View in EDS

Inflammatory markers in prostate cancer: potential roles in risk stratification and immune profiling.

Saved in:
Bibliographic Details
Title: Inflammatory markers in prostate cancer: potential roles in risk stratification and immune profiling.
Authors: Burzinskis E; Department of Laboratory Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania., Janulaityte I; Department of Laboratory Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania., Jievaltas M; Department of Urology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Skaudickas D; Department of Urology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Burzinskiene G; Department of Obstetrics and Gynecology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Dainius E; Department of Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania., Naudziunas A; Lithuanian, University of Health Sciences, Internal Medicine Department, Kaunas, Lithuania., Vitkauskiene A; Department of Laboratory Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Source: Journal of immunotoxicology [J Immunotoxicol] 2025 Dec; Vol. 22 (1), pp. 2497776. Date of Electronic Publication: 2025 Apr 28.
Publication Type: Journal Article
Language: English
Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 101201960 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1547-6901 (Electronic) Linking ISSN: 1547691X NLM ISO Abbreviation: J Immunotoxicol Subsets: MEDLINE
Imprint Name(s): Publication: London : Informa Healthcare
Original Publication: Philadelphia, PA : Taylor & Francis Health Sciences, c2004-
MeSH Terms: Prostatic Neoplasms*/immunology , Prostatic Neoplasms*/diagnosis , Prostatic Neoplasms*/blood , Biomarkers, Tumor*/blood , Biomarkers, Tumor*/metabolism , Inflammation*/immunology , Prostate*/pathology , Inflammation Mediators*/metabolism , Inflammation Mediators*/blood, Humans ; Male ; Middle Aged ; Aged ; Prospective Studies ; Risk Assessment ; Biopsy ; Triggering Receptor Expressed on Myeloid Cells-1 ; Cytokines/blood ; Cytokines/metabolism
Abstract: Inflammation plays a critical role in prostate cancer (PCa) pathophysiology, yet the diagnostic value of specific inflammatory markers remains unclear. This study evaluates the association between circulating and tissue inflammatory markers with PCa presence and their potential as biomarkers for risk stratification. This prospective study analyzed serum and prostate biopsy samples from 60 patients with PCa and 22 cancer-free controls. Concentrations of inflammatory markers, including IL-2, IL-4, IL-10, IL-13, IL-33, Oncostatin M, TNFα, PDGF-BB, and TREM-1, were measured using Luminex technology. Statistical analyses included the Mann-Whitney test, logistic regression, and ROC curve analysis to assess differences and diagnostic performance. PCa patients exhibited significantly higher serum levels of IL-2 ( p  = 0.001), IL-10 ( p  < 0.001), IL-33 ( p  < 0.001), Oncostatin M ( p  = 0.018), and TNFα ( p  = 0.017) compared to controls. In contrast, biopsy tissue levels of IL-4 ( p  < 0.001), IL-10 ( p  < 0.001), IL-13 ( p  = 0.004), Oncostatin M ( p  = 0.012), PDGF-BB ( p  = 0.039), and TREM-1 ( p  = 0.013) were significantly lower in PCa patients, suggesting an inverse association. IL-10 (inverse) and IL-4 (inverse) in biopsy tissue showed high specificity in ROC analysis (AUC = 0.788 and 0.804, respectively), while IL-2 and IL-33 in serum were positively associated with PCa risk. This study suggests that IL-4, IL-10, and IL-13 in biopsy tissue may serve as biomarkers of a protective effect, while elevated IL-2 and IL-33 in serum are associated with an increased risk of PCa. These findings highlight the potential of inflammatory markers in PCa risk stratification, warranting further investigation in larger cohorts.
Contributed Indexing: Keywords: IL-10; IL-4; Prostate cancer; biomarkers; cytokines; inflammation
Substance Nomenclature: 0 (Biomarkers, Tumor)
0 (Triggering Receptor Expressed on Myeloid Cells-1)
0 (Cytokines)
0 (Inflammation Mediators)
Entry Date(s): Date Created: 20250429 Date Completed: 20250429 Latest Revision: 20250429
Update Code: 20250429
DOI: 10.1080/1547691X.2025.2497776
PMID: 40296239
Database: MEDLINE
Description
Abstract:Inflammation plays a critical role in prostate cancer (PCa) pathophysiology, yet the diagnostic value of specific inflammatory markers remains unclear. This study evaluates the association between circulating and tissue inflammatory markers with PCa presence and their potential as biomarkers for risk stratification. This prospective study analyzed serum and prostate biopsy samples from 60 patients with PCa and 22 cancer-free controls. Concentrations of inflammatory markers, including IL-2, IL-4, IL-10, IL-13, IL-33, Oncostatin M, TNFα, PDGF-BB, and TREM-1, were measured using Luminex technology. Statistical analyses included the Mann-Whitney test, logistic regression, and ROC curve analysis to assess differences and diagnostic performance. PCa patients exhibited significantly higher serum levels of IL-2 ( p  = 0.001), IL-10 ( p  &lt; 0.001), IL-33 ( p  &lt; 0.001), Oncostatin M ( p  = 0.018), and TNFα ( p  = 0.017) compared to controls. In contrast, biopsy tissue levels of IL-4 ( p  &lt; 0.001), IL-10 ( p  &lt; 0.001), IL-13 ( p  = 0.004), Oncostatin M ( p  = 0.012), PDGF-BB ( p  = 0.039), and TREM-1 ( p  = 0.013) were significantly lower in PCa patients, suggesting an inverse association. IL-10 (inverse) and IL-4 (inverse) in biopsy tissue showed high specificity in ROC analysis (AUC = 0.788 and 0.804, respectively), while IL-2 and IL-33 in serum were positively associated with PCa risk. This study suggests that IL-4, IL-10, and IL-13 in biopsy tissue may serve as biomarkers of a protective effect, while elevated IL-2 and IL-33 in serum are associated with an increased risk of PCa. These findings highlight the potential of inflammatory markers in PCa risk stratification, warranting further investigation in larger cohorts.
ISSN:1547-6901
DOI:10.1080/1547691X.2025.2497776